TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Studies of Pandemic Influenza (H1N1) 2009 Vaccine in Bergen

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Signed informed consent Subjects able to understand and comply with the study protocol and complete the Adverse Event Form Subjects able to attend the scheduled visits for the kinetic study~Exclusion Criteria:~* Persons with a history of anaphylaxis or serious reactions to any vaccine~* Person with known hypersensitivity to any of the vaccine components~* Persons who have had a temperature \>38oC during the previous 72 hours~* Persons who have had an acute respiratory infection during the last 7 days~* Suspected non-compliance

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Pandemic influenza H1N1 vaccine (Type: EXPERIMENTAL): Influenza vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are 20 - 75 years old~* Patients who are under dietary management and taking therapeutic exercise for diabetes over 8 weeks before administration of investigational drug~* Patients whose HbA1c is ≥6.5% and \<10.0%~* Patients who were not administered diabetes therapeutic drugs prohibited for concomitant use within 8 weeks before administration of investigational drug.~Exclusion Criteria:~* Patients with type 1 diabetes, diabetes mellitus caused by pancreas impairment, or secondary diabetes (Cushing disease, acromegaly, etc)~* Patients who are accepting treatments of arrhythmias~* Patients with serious diabetic complications~* Patients who are the excessive alcohol addicts~* Patients with severe hepatic disorder or severe renal disorder.~* Patients who are pregnant, lactating, and probably pregnant patients, and patients who can not agree to contraception

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- MP-513 10 mg, once a day, for 4 weeks (Type: EXPERIMENTAL): None
- MP-513 20 mg, once a day, for 4 weeks (Type: EXPERIMENTAL): None
- Placebo of MP-513 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Self-administered Lidocaine Gel for Pain-control During Cervical Preparation for Dilation and Evacuation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women 18 and older~* Intrauterine pregnancy ≥16 weeks gestation~* English speaking competency~* Willing and able to sign consent forms~* Agree to comply with study procedures~Exclusion Criteria:~* Women less than 18 years of age~* IV conscious sedation~* Known allergy to study medication (lidocaine)~* Any women not meeting inclusion criteria above will be excluded from participation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Self-administered Gel (Type: EXPERIMENTAL): Patient-administered, vaginal lidocaine gel (2%)--inserted 15 minutes prior to cervical preparation procedure
- Paracervical Block (Type: ACTIVE_COMPARATOR): Provider-administered lidocaine (1%) paracervical injection--administered immediately prior to tenaculum placement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vaccination Against Influenza in Autoimmune Diseases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients presenting autoimmune and systemic diseases,~* treating or not with steroids, and/or immunosuppressants and/or biotherapies, especially vasculitis, scleroderma, Sjogren's syndrome and systemic lupus (main groups)~Exclusion Criteria:~* Absence of informed consent~* Disease which did not responded to the above criteria~* Active infection at time of vaccination~* HIV infection~* History of Guillain-Barre syndrome~* Allergy to one component of the vaccine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Evaluation of vaccines against flu (Type: EXPERIMENTAL): Evaluation of vaccines against flu

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older;~* HSV-2 seropositive by Western Blot;~* not receiving any drugs with known anti-HSV-2 activity for study duration;~* history of primary genital herpes infection within past 6 months OR history of 4 or more HSV recurrences per year during the past year OR 4 or more recurrences per year prior to initiation of suppressive antiviral therapy; or shedding HSV-2 from genital mucosa on \>25% of days in shedding session performed at the VRC within the last 2 years.~* able to comply with the study protocol;~* women of child bearing potential who are sexually active with men must be using a medically accepted method of contraception as judged by the investigator;~* women of child-bearing potential must have a negative pregnancy test (urine) at screening visit;~* in general good health, without other serious medical conditions and specifically with normal renal and hepatic function, as determined by the patient's medical history;~* planning to remain resident in the area of the study center for the duration of the study participation;~* HIV seronegative.~Exclusion Criteria:~* hypersensitivity to acyclovir or valacyclovir;~* pregnant women;~* HIV positive or other immunosuppressed state, including chronic steroid use. Intermittent nasal or topical steroids are acceptable

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- valacyclovir (Type: ACTIVE_COMPARATOR): None
- high dose valacyclovir (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical presentation compatible with alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years at the time of Screening. Total disease duration greater than 10 years is permitted.~* At least 50% scalp hair loss, as defined by a Severity of Alopecia Tool (SALT) score ≥50, at Screening and Baseline.~* Willing to comply with the study visits and requirements of the study protocol.~Exclusion Criteria:~* Treatment with other medications or agents within 1 month of Baseline or during the study that may affect hair regrowth or immune response.~* Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or other scalp condition that may interfere with the SALT assessment, or untreated actinic keratosis anywhere on the body at Screening and/or Baseline.~* Treatment with systemic immunosuppressive medications within 3 months of Screening or during the study, or biologics within 6 months of Screening or during the study.~* Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study drug.~* Clinically significant medical condition, psychiatric disease, or social condition, as determined by the Investigator, that may unfavorably alter the risk-benefit of study participation, adversely affect study compliance, or confound interpretation of study results.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received CTP-543 matched placebo tablets, orally, twice daily (BID) for up to 24 weeks.
- CTP-543 8 mg BID (Type: EXPERIMENTAL): Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
- CTP-543 12 mg BID (Type: EXPERIMENTAL): Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia （SAA） Patient

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Previous diagnosis of refractory severe aplastic anemia, not meeting partial response criteria after at least one treatment course of immunosuppressive therapy, not suitable or unwilling to do hematopoietic stem cell transplantation.~2. Platelet count ≤ 30×109/L.~3. Signed informed consent.~Exclusion Criteria:~1. Bleeding and/or Infection not adequately responding to appropriate therapy.~2. Patients with a PNH clone size in neutrophils of ≥50%.~3. Treatment with immunosuppressive therapy within 6 months prior to study entry.~4. Any laboratory or clinical evidence for HIV infection. Any clinical history for hepatitis C infection; chronic hepatitis B infection; or any evidence for active hepatitis at the time of subjects screening.~5. ALT\> 2.5 x upper limit of normal (ULN), AST\> 2.5 x upper limit of normal (ULN) DBLI\> 1.5 x upper limit of normal (ULN), Scr\> upper limit of normal (ULN).~6. Subjects diagnosed with cirrhosis or portal hypertension.~7. Subjects diagnosed with tumor.~8. Patients with any prior history of congestive heart failure, arrhythmia, and peripheral arteriovenous thrombosis within 1 year. With a history of myocardial infarction or cerebral infarction within 3 months.~9. ECOG Performance Status of 3 or greater.~10. Female subjects who are nursing or pregnant within 6 months.~11. Subjects cannot take effective contraception.~12. Subjects have participated in other clinical trial within the 3 months prior to study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hetrombopag Olamine (Type: EXPERIMENTAL): Hetrombopag will be started at 7.5 mg/day and uptitrated according to the platelet count.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound Guided Infraclavicular Brachial Plexus Block Using Levo-bupivacaine Alone or Combined With Dexmedetomidine for Hand and Forearm Surgeries

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 20-65 years old.~* American society of anesthesiologist physical status (ASA): I-II.~* Operation: forearm \& hand surgeries.~Exclusion Criteria:~* Patients with chronic pain~* Those using chronic analgesic medications~* History of brachial plexus injury~* Allergy to the study drugs~* Hepatic or renal insufficiency or infection at the site of injection

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- group Levo-bupivacaine (Type: OTHER): Group A (20 patients): Anesthesia will be performed with 35 ml of 0.5% levo-bupivacaine plus 1ml normal saline under the guidance of ultrasound for infraclavicular brachial plexus block.
- group levo-bupivacaine plus 50µg dexmedetomidine (Type: OTHER): Group B (20 patients): Anesthesia will be performed with 35 ml of 0.5% levo-bupivacaine plus 50µg dexmedetomidine under the guidance of ultrasound for infraclavicular brachial plexus block.
- group levo-bupivacaine plus 100µg dexmedetomidine (Type: OTHER): Group C (20 patients): Anesthesia will be performed with 35 ml of 0.5% levo-bupivacaine plus 100µg dexmedetomidine under the guidance of ultrasound for infraclavicular brachial plexus block.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Hunterase

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The patient has a diagnosis of Hunter syndrome based upon biochemical criteria:~   * as measured in plasma, leukocytes, or fibroblasts,~     * a deficiency in iduronate-2-sulfatase (I2S) enzyme activity of ≤ 10 % of the lower limit of the normal range~  * That corresponds to one or more of the following:~     * a normal enzyme activity level of one other sulfatase~    * Confirmed as MPS2 by genetic test results~    * shows clinical symptoms/ visible signs of MPS2~2. \< 6 years old and male~3. Patients who are able to comply with the study requirements~4. The patient's parent(s), or patient's legal guardian must have given voluntary written consent to participate in the study~Exclusion Criteria:~1. The patient has had a tracheostomy~2. The patient has known severe hypersensitivity or shock to any of the components of idursulfase~3. The patient has received treatment with another investigational therapy within 30 days prior to enrollment~4. History of a stem cell transplant~5. The patient has known severe hypersensitivity or shock to any of the components of test drug(excipient etc)

- Gender: MALE
- Minimum Age: None
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Test drug (Type: EXPERIMENTAL): Idursulfase-beta

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving Memory Performance by Applying Cognitive Training

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV infection, diagnosed for \> 6 months~* Currently on treatment with antiretroviral medications for \> 3 months~* Self-reported medication adherence at less than 90%~* Lives within 15 miles of the research site in stable housing and with no plans to move from the area in the next 3 months~Exclusion Criteria:~* Current substance use disorder~* Any drug use other than alcohol or marijuana in the past year~* Pregnancy~* English non-fluency or illiteracy~* ≤ 8th grade education~* serious neurological disorders, including HIV dementia~* traumatic brain injury~* severe mental illness or acute psychiatric distress~* impaired mental status

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Active Cognitive Training (ACT) (Type: EXPERIMENTAL): The ACT group will complete 12 individual sessions across 6-10 weeks. Sessions will utilize four commercially available memory-training programs from PSSCogRehab 2012, published by Psychological Software Service. The four programs used will be: (1) Sequence recall of digits - auditory (SRD-A), (2) Sequenced Recall Reversed Digits - Auditory (SRRD-A), (3) Sequenced Recall of Words - Visual (SRW-V), and (4) Verbal memory - categorizing (VM-C). In each training session, participants will complete each of the four memory training programs twice.
- Control (CON) (Type: SHAM_COMPARATOR): The CON group will also complete 12 total sessions across 6-10 weeks. The same four computer programs from PSSCogRehab 2012, published by Psychological Software Service, will be used in the control group sessions. However, the control program will identify the correct responses to participants, such that they do not need to engage their working memory to answer the questions correctly.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PCV10 Immunogenicity Study Nepal 2015

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female, aged 40-60 days at time of first study vaccination~* Parent/ guardian of participant is willing and able to give informed consent for participation in the study.~* In good general health as determined by:~  * medical history~ * physical examination~ * clinical judgment of the investigator~* Participants residing in Kathmandu~* Parents able (in the Investigators opinion) and willing to comply with all study requirements.~Exclusion Criteria:~* Parent/guardian unwilling or unable to give written informed consent to participate in the study~* Previous immunisation (excluding BCG, OPV, hepatitis B, measles or other government vaccine programme) or planned vaccination during the study period with vaccine not foreseen by this study protocol except influenza vaccine and oral polio vaccination as recommended locally.~* Premature birth (\<37 weeks gestation)~* Previous hospital admission except where hospital stay would not compromise the study in the judgment of the investigator.~* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.~* Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding the vaccination, or planned use during the study period.~* Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 8 Weeks
- Healthy Volunteers: t

Study Arms:
- 6 + 10 weeks of age PCV10 priming (Type: ACTIVE_COMPARATOR): 10 valent pneumococcal conjugate vaccine administered (PCV10) at 6 and 10 weeks of age with a booster at9 months of age and routine vaccines administered as per the Nepal EPI schedule
- 6 + 14 weeks of age PCV10 priming (Type: ACTIVE_COMPARATOR): 10 valent pneumococcal conjugate vaccine administered (PCV10) at 6 and 14 weeks of age with a booster at 9 months of age and routine vaccines administered as per the Nepal EPI schedule

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects and Safety of Menthol on Blood Pressure and Metabolic Parameters in Prehypertensive and Mild Hypertensive Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Blood pressure: 120mmHg≤SBP\<160mmHg, and/or 80mmHg≤DBP\<100mmHg~Exclusion Criteria:~* Diabetes~* Hypertension: SBP≥160mmHg, or DBP≥100mmHg~* known allergy to trial drugs~* Myocardial infarction or cerebrovascular accident in the year preceding the trial~* Clinical Congestive Heart Failure~* Secondary hypertension~* Pregnancy or lactating women~* Malignant tumor~* Gastroesophageal reflux or gastroduodenal ulcer~* History of hepatitis or cirrhosis~* History of kidney disease~* Body weight﹤35Kg

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Menthol (Type: ACTIVE_COMPARATOR): Interventions Drug: Menthol Arms: Group 1
- Placebo (Type: PLACEBO_COMPARATOR): Interventions Drug: Placebo Arms: Group 2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete